The US president is playing a different game where the normal rules of engagement do not apply.
A patent dispute between Teva Pharmaceuticals and Bristol Myers Squibb, over a blood thinning drug, is playing out in the Irish courts.
The pharma firm is building a drug manufacturing site in Dublin, due for completion next year, and has been piling several tranches of capital into a new subsidiary to manage it.
John Power's Aerogen is transitioning to the world of biopharmaceutics. The Galway entrepreneur talks about securing backing from the Gates Foundation, and the prospect of raising more funds later this year.
Trump’s first-term tariffs were small and on a limited number of goods. A blanket tariff on all imports of at least 10% is almost incomparable and would have an outsized impact on Ireland.
Ireland hosts several international pharmaceutical giants and the companies are keen to get their voices heard in Brussels via Ireland.
Pfizer, Novartis and several other major companies want Ireland to delay new EU wastewater treatments rules, claiming they will cost the industry dearly and impact FDI.
Having last year closed a $45m series B, Irish biotech company Nuritas has revealed it is building its new North American headquarters in Connecticut. CEO Dr Nora Khaldi is also moving to the US to lead the strategic expansion.
© 2025 Currency Media Limited
